KCTD9: A Potential Drug Target and Biomarker (G54793)

Target Name: KCTD9

NCBI ID: G54793

KCTD9

KCTD9: A Potential Drug Target and Biomarker

KCTD9, also known as GABA-ZYF2, is a protein that is expressed in various tissues and cells in the brain, including neurons, glial cells, and microglia. It is a key regulator of GABA signaling, a critical neurotransmitter that plays a crucial role in the regulation of neural activity and behavior. GABA is known for its ability to calm neural activity, and deficiencies in GABA signaling have been linked to a number of neurological and psychiatric disorders, including epilepsy, anxiety, and depression.

KCTD9 has also been shown to play a role in the regulation of ion channels, which are responsible for the flow of electrical signals through cells. The ability of KCTD9 to regulate ion channels has led to its potential as a drug target. By targeting KCTD9 with small molecules, researchers may be able to modulate its activity and improve the treatment of neurological and psychiatric disorders.

In addition to its potential as a drug target, KCTD9 has also been shown to be a potential biomarker for a number of neurological disorders. The GABA-ZYF2 gene has been shown to be significantly downregulated in individuals with certain neurological disorders, including epilepsy, anxiety, and depression. By identifying individuals with reduced KCTD9 levels, researchers may be able to develop new diagnostic tools for these disorders and potentially target KCTD9 as a treatment.

The search for new drug targets and biomarkers is an ongoing process in the field of neuroscience, and the potential of KCTD9 as a drug target and biomarker is just one of many promising targets that researchers are exploring. With further research, KCTD9 has the potential to not only improve our understanding of the underlying mechanisms of neurological and psychiatric disorders, but also lead to the development of new and effective treatments.

Protein Name: Potassium Channel Tetramerization Domain Containing 9

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex, which mediates the ubiquitination of target proteins, leading to their degradation by the proteasome

The "KCTD9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets